Introduction: Chronic migraines (CM) affect a significant portion of the Saudi population, yet patients lack access to Eptinezumab, a drug with proven preventive efficacy and a strong safety record. This analysis aims to evaluate Eptinezumab’s effectiveness in managing CM and advocate for its availability to Saudi patients. Methods: We performed a meta-analysis of data from two clinical trials registered on ClinicalTrials.gov (Identifiers: NCT02275117 and NCT02974153), involving patients treated with 100mg or 300mg doses of Eptinezumab or a placebo, delivered through IV infusion. Results: The analysis included data from over 1400 individuals, revealing that Eptinezumab significantly reduces MMDs, with the 300mg dosage being more effective than the 100mg. The 300mg dose reduced MMDs by an average of -8.2 days, while the 100mg dose achieved a reduction of -7.7 days. Discussion: Our findings confirm the substantial benefits of Eptinezumab in reducing the burden of CM, with both dosages showing effectiveness. The 300mg dose, in particular, provides a greater reduction in MMDs. These results, paired with the drug’s excellent safety profile, suggest that Eptinezumab would be a valuable addition to the treatment options available to Saudi patients. Conclusion: The administration of Eptinezumab at the studied dosages demonstrates prolonged preventive effects on CM with minor side effects. This supports the potential for introducing Eptinezumab in Saudi Arabia, proposing it as a promising CM treatment to improve patient outcomes.